Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- irinotecan liposomal
- Prepopik (citric acid/magnesium oxide/sodium picosulfate)
Interactions between your drugs
sodium picosulfate irinotecan liposomal
Applies to: Prepopik (citric acid/magnesium oxide/sodium picosulfate), irinotecan liposomal
GENERALLY AVOID: Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.
MANAGEMENT: In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician. However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.
References (1)
- (2001) "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn
Drug and food interactions
sodium picosulfate food
Applies to: Prepopik (citric acid/magnesium oxide/sodium picosulfate)
ADJUST DOSING INTERVAL: Bowel cleansing products can increase the gastrointestinal transit rate. Oral medications administered within one hour of the start of administration of the bowel cleansing solution may be flushed from the gastrointestinal tract and not properly absorbed.
MANAGEMENT: Patients should be advised that absorption of oral medications may be impaired during bowel cleansing treatment. Oral medications (e.g., anticonvulsants, oral contraceptives, antidiabetic agents, antibiotics) should not be administered during and within one hour of starting bowel cleansing treatment whenever possible. However, if concomitant use cannot be avoided, monitoring for reduced therapeutic effects may be advisable.
References (2)
- "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
- (2022) "Product Information. Prepopik (citric acid/magnesium oxide/sodium picosulfate)." Ferring Pharmaceuticals Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Abraxane
Abraxane is an antineoplastic medication used in the treatment breast cancer. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Onivyde
Onivyde (irinotecan liposomal) is an injectable prescription chemotherapy medicine that may be used ...
Tarceva
Tarceva (erlotinib) is a chemotherapy medicine used in the treatment of non-small cell lung cancer ...
Sutent
Sutent is a cancer medicine that is used to treat certain types of advanced or progressive tumors ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.